Table 3.

Univariable and multivariable analysis of outcomes

	Recurrence RR (95% CI)	DFS HR (95% CI)	DSS HR (95% CI)	OS HR (95% CI)
UNIVARIABLE
Age	1.02 (0.96–1.09)	1.03 (0.97–1.09)	1.01 (0.93–1.10)	1.04 (0.97–1.12)
Center	0.75 (0.26–2.16)	2.25 (0.69–7.30)	0.67 (0.11–3.99)	1.67 (0.39–6.97)
Smoking	0.58 (0.23–1.48)	0.80 (0.32–2.03)	1.5 (0.25–8.98)	1.33 (0.29–5.96)
ACE-27  Mild  Moderate+Severe	1.28 (0.42–3.89) 1.54 (0.30–7.87)	0.85 (0.21–3.41) 1.86 (0.41–8.42)	0.78 (0.08–7.12) 1.29 (0.14–11.84)	0.66 (0.07–6.01) 1.52 (0.17–13.92)
Subsite (Tonsil vs. BOT)	0.33 (0.03–3.20)	0.50 (0.05–5.51)	1	1
ECE	0.5 (0.15–1.66)	0.63 (0.20–1.91)	1.0 (0.14–7.10)	0.75 (0.17–3.35)
PNI	0.75 (0.17–3.35)	1 (0.25–4.00)	2.0 (0.18–22.06)	2.0 (0.18–22.1)
LVI	1.0 (0.29–3.45)	0.71 (0.27–3.25)	1.0 (0.14–7.10)	0.75 (0.17–3.35)
Margins	0.50 (0.07–3.71)	0.62 (0.08–4.56)	0.19 (0.02–1.50)	0.243 (0.03–1.87)
Path T Stage (1 and 2 vs. 3 and 4)	NA	NA	NA	NA
Lymph node (<=4 vs. >4)	NA	NA	NA	NA
Adjuvant therapy	0.07 (0.02–0.31)	0.19 (0.08–0.43)	0.48 (0.14–1.63)	0.50 (0.19–1.29)
MULTIVARIABLE
Age	0.96 (0.86–1.07)	0.97 (0.89–1.05)	0.98 (0.88–1.09)	0.99 (0.91–1.1)
Smoking	1.28 (0.27–6.16)	4.41 (0.43–45.03)	4.22 (0.26–67.32)	5.63 (0.35–89.67)
Adjuvant therapy	0.096 (0.02–0.47)	0.067 (0.01–0.62)	0.22 (0.02–2.57)	0.18 (0.01–2.4)

Abbreviations: RR – Relative Risk; HR – Hazard ratio; CI – Confidence interval; DFS – Disease free survival; DSS – Disease specific survival; OS – Overall survival; ACE-27 – Adult Comorbidity Evaluation-27; BOT – Base of tongue; ECE – Extracapsular extension; PNI – Perineural invasion; LVI – Lymphovascular invasion; NA – Not applicable